Study of new pathogenetic mechanisms of diabetic retinopathy development in patients with diabetic foot syndrome
DOI:
https://doi.org/10.12775/JEHS.2021.11.04.024Keywords
diabetes mellitus, diabetic retinopathy, diabetic foot syndrome, nitric oxide, thiobarbituric acid, diabetic maculopathy, diabetic macular edemaAbstract
Introduction and purpose. Diabetes is one of the underlying causes of blindness and other long-term negative consequences that significantly affect patients’ quality of life. The study aimed to determine the indicators characterizing the pathogenetic mechanisms of the development of vascular dysfunction, in particular diabetic retinopathy (DR), and the relationship of these changes with nitric oxide. Material and methods. There were 2114 patients with various surgical diseases under observation (including 1073 patients with purulent-septic soft tissue diseases), among them there were 193 patients with type 2 diabetes mellitus (DM) and 134 patients with Wagner stage 2-5 diabetic foot syndrome (DFS) and diabetic retinopathy in the main group (268 eyes). The comparison group included 59 patients (118 eyes) of the corresponding age with DM without DFS and DR. Both groups were the same in age and gender. Results. The level of the end products of nitric oxide metabolism in peripheral blood was found to be 1.78 times (p<0.01) higher compared with patients without DR. A decrease in the activity of superoxide dismutase (SOD) in patients with DR was by 1.56 times (p<0.01) lower relative to the comparison group. The content of thiobarbituric acid (TBA)-active products in the peripheral blood of patients of the main group exceeded by 1.58 times (p <0.01) the reference values of patients without DR. When determining the content of S-nitrosithiols, an increase in these indicators in the main group was found to be 2.38 times (p<0.01). Patients in the main group with DR also showed a 5.13-fold (p<0.001) increase in peripheral blood homocysteine concentration. NO is known to have both positive and harmful effects depending on its concentration. On the one hand, NO causes relaxation of blood vessels by reducing blood pressure, prevents platelet aggregation and adhesion, limits LDL cholesterol oxidation, suppresses smooth muscle cell proliferation, and reduces the expression of proinflammatory genes that are associated with atherogenesis. It is known that NO can have both positive and harmful effects, depending on its concentration. On the one hand, NO causes relaxation of blood vessels, reducing blood pressure, prevents platelet aggregation and adhesion, limits the oxidation of LDL cholesterol, suppresses the proliferation of smooth muscle cells, and reduces the expression of pro-inflammatory genes that are associated with atherogenesis. On the other hand, NO interacts with O2-, leading to the inactivation of NO and the production of peroxynitrite, which post-transcriptionally modifies proteins and negatively affects their function. This can contribute to endothelial dysfunction by stimulating the production of inflammatory mediators and lipid peroxidation and thus increasing cell permeability. Conclusions. The findings show that the patients with diabetes mellitus complicated by retinopathy and DFS had a significant increase in the content of nitric oxide in the peripheral blood, the cause of which is hyperglycemia. The use of an intercellular mediator (nitric oxide), which contributes to the physiological regulation of the hemodynamics of the eye, protects vascular endothelial cells from pathogenic factors of ischemia, will help clinicians choose an effective pharmacological therapy appropriate for a particular patient and a particular eye.
References
Owyong М, Schwartz SG, Scott IU. An Update on the Genetics of Diabetic Retinopathy. Retina Today [Internet]. 2017. Available from: http://retinatoday. com/2017/03/an-update-on-the-genetics-of-diabetic-retinopathy.
Yau JW. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012; 35 (3):556-64.
Coucha M, Elshaer SL, Eldahshan WS, Mysona BA, El-Remessy AB. Molecular mechanisms of diabetic retinopathy: potential therapeutic targets. Middle. East. Afr. J. Ophthalmol. 2015 Apr-Jun; 22 (2):135-44.
Pshenichnov MV. Risk factors and patterns of manifestation of macular edema in patients with type II diabetes mellitus. Avtoreferat. Krasnoyarsk. 2010: 22.
Veselovskaya N.N., Veselovskaya Z.F. Basic research in ophthalmology - a modern perspective of new approaches to primary and secondary prevention of vascular diseases of the visual organ. Ophthalmology. 2015; 1(01): 11-17.
Polovina MM, Potpara TS. Endothelial dysfunction in metabolic and vascular disorders. Postgrad Med. 2014; 126 (2):38-53.
Bilyaeva O.A., Krizhevsky V.V., Rybyanets L.I., Ulanovich L.I., Ivanchenko R.V. Optimization of complex treatment of purulent necrotic processes in patients with diabetic foot syndrome and financial aspects. Klinicheskaya hirurgiya. 2014; 11(3): 3-7.
Pokydjko A.A., Zhmur T.P., Zarezanko A.V., Funikov A.V., Yarmak O.A., Osadchiy A.V. Features of the wound process in patients with hospital wounds and in patients with diabetic foot syndrome. Harkivska hirurgichna shkola. 2019; 2(95): 214-218.
Bezditko P.A., Klimenko V.V. Molecular mechanisms of pathogenesis of diabetic retinopathy. Archiv ophthalmology. 2017; 5 (3): 92-96.
Kertes P.J., Johnson T.M. Evidence Based Eye Care. Lippincott Williams & Wilkins. 2007; 6964-6967.
Rahimi Z, Moradi M, Nasri H. A systemic review of the role of rennin angiotensin aldosterone system genes in diabetes mellitus, diabetic retinopathy and diabetic neuropathy. J. Res. Med. Sci. 2014; 19 (11):1090-8.
Krushinskaya Z.G., Uyzvenko T.U., Marchenko O.V. The influence of etiological and social factors on the development and course of diabetic foot syndrome. Endokrinology. 2019: 24 (1): 17-23.
Marchenko O.V. Analysis of negative results of treatment of diabetic foot syndrome in an outpatient setting. Meghdunarodmiy endokrinologicheskiy ghurnal. 2017; 13(2): 181-185.
Forstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat. Clin. Pract. Cardiovasc. Med. 2008; 5:338-49.
Rangasamy S, McGuire PG, Das A. Diabetic retinopathy and inflammation: Novel therapeutic targets. Middle East Afr J Ophthalmol. 2012; 19:52-9.
Rubenstein DA, Yin W. Рlatelet-activation mechanisms and vascular remodeling. Compr. Physiol. 2018; 8(3):1117-56.
Babik B, Peták F, Agócs S, Blaskovics I, Alács E, Bodó K, et al. Diabetes mellitus: endothelial dysfunction and changes in hemostasis. OrvHetil. 2018; 159 (33):1335-45.
Sivaprasad S, Gupta B, Crosby-Nwaobi R, Evans J. Prevalence of diabetic retinopathy in various ethnic groups: a worldwide perspective. Surv. Ophthalmol. 2012; 57 (4):347-70.
Mammadzada P., Gudmundsson J., Kvanta F., Andre H. Differential hypoxic response of human choroidal and retinal endothelial cells proposes tissue heterogeneity of ocular angiogenesis. Acta Ophthalmologica. 2016; 94 (8): 805-814.
Stem MS, Gardner TW. Neurodegeneration in the pathogenesis of diabetic retinopathy: molecular mechanisms and therapeutic implications. Curr. Med. Chem. 2013; 20 (26):3241-50.
Seluytina S.N., Seluytin A.Yu., Palj A.I. Modification of the determination of the concentration of TBK-active products of blood serum. Klin.lab.diagnostica. 2000; 2: 8-11.
Kostyuk V.A., Potapovich A.I., Kovakeva Zh.V. A simple and sensitive method for determining the activity of superoxide dismutase, based on the oxidation reaction of quercetin. Voprosi med. Himii. 1990; 36 (2): 88-91.
Grishem M.B., Dghonson G.G., Lankaster Dg.P. Quantification of nitrates and nitrites in extracellular fluids. Metodi Enzimol. 1996; 268: 237-246.
Stamler J.S. S-nitrosothiols in blood: role, amount and methods of analysis], S-нитрозотиолы в крови: роль, количество и методы анализа. Circ Res. 2004; 94 (4): 414-417.
Adela Р., Nethi С.К., Bagul P.К., Barui А.К., Mattapally С., Kuncha М., [et al.] Hyperglycemia Increases Nitric Oxide Production in Diabetes: A PLoS One Study of South Indian Patients. Plos One. 2015; 10 (4): 25-27.
Pacher, P. et al. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 2006; 58: 389-462.
Straznicky NE, Grima MT, Lambert EA. Arterial norepinephrine concentration is inversely and independently associated with insulin clearance in obese individuals with metabolic syndrome. J. Clin. Endocrinol. Metab. 2015; 100 (4):1544-50.
Vindeirinho J, Santiago AR, Cavadas C, Ambrósio AF, Santos PF. The Adenosinergic System in Diabetic Retinopathy. J Diabetes Res. 2016; 2016:4270301.
Zheng Y, He M, Congdon N. The worldwide epidemic of diabetic retinopathy. Indian J. Ophthalmol. 2012; 60 (5):428-31.
Downloads
Published
How to Cite
Issue
Section
License
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 487
Number of citations: 0